IMS 2025: Patient perspectives on outpatient step-up dosing with bispecific antibodies for relapsed myeloma
Published:
Patients valued the increased choice, freedom and privacy that came with outpatient care. One told us they “felt less confined and had more freedom,” while another appreciated “not being woken up regularly for observations.” Many also highlighted that the support from the healthcare team remained strong and reliable. Five out of seven patients said they felt well educated on the pathway and on potential toxicities.
Sign up and become a member of the Myeloma UK HCP Hub
Access exclusive content like this and join in the conversation.
Already have an account?